Medincell's partner teva provided treatment insights into switching to uzedy® from perseris®

Montpellier, france--(business wire)--new data presented by teva at ecnp 2024* demonstrate switching to uzedy at four weeks after the last dose of once-monthly perseris® (rbp-7000) provided the most comparable pharmacokinetic (pk) profile based on relevant simulations, with comparable doses identified. perseris manufacturer announced in july 2024 the discontinuation of its commercialization. teva already presented in june 2024 data informing clinical strategies for switching patients to uzedy f.
TEVA Ratings Summary
TEVA Quant Ranking